Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014

MMWR. Morbidity and Mortality Weekly Report
Paul MehtaKevin Horton

Abstract

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive and fatal neuromuscular disease; the majority of ALS patients die within 2-5 years of receiving a diagnosis (1). Familial ALS, a hereditary form of the disease, accounts for 5%-10% of cases, whereas the remaining sporadic cases have no clearly defined etiology (1). ALS affects persons of all races and ethnicities; however, whites, males, non-Hispanics, persons aged >60 years, and those with a family history of ALS are more likely to develop the disease (1-3). No cure for ALS has yet been identified, and the lack of proven and effective therapeutic interventions is an ongoing challenge. Current treatments available do not cure ALS but have been shown to slow disease progression. Until recently, only one drug (riluzole) was approved to treat ALS; however, in 2017, the Food and Drug Administration approved a second drug, edaravone (4).

References

Mar 7, 2014·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Wendy E KayeJennifer Wu
Jul 25, 2014·JAMA : the Journal of the American Medical Association·D Kevin HortonVinicius C Antao

❮ Previous
Next ❯

Citations

Nov 15, 2018·International Journal of Environmental Research and Public Health·Germán Sánchez-DíazVerónica Alonso-Ferreira
Mar 21, 2019·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Rituparna BhattacharyaPaul Mehta
Nov 23, 2018·Acta Neuropathologica·Madelyn E McCauley, Robert H Baloh
Jul 30, 2019·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·James L Nuzzo
May 31, 2020·International Journal of Molecular Sciences·Yeomin Yun, Yoon Ha
Aug 21, 2020·Medicinal Research Reviews·Michail S KukharskyVladimir L Buchman
Sep 11, 2019·Nature Reviews. Neurology·Yujun HouVilhelm A Bohr
Mar 3, 2020·Frontiers in Physiology·Sandra Carrera-JuliáEraci Drehmer
Jun 26, 2020·Frontiers in Molecular Neuroscience·Ravinder Malik, Martina Wiedau
Nov 22, 2018·MMWR. Morbidity and Mortality Weekly Report·Paul MehtaKevin Horton
Sep 10, 2020·Acta Neurologica Scandinavica·Kyla A McKayFabian Taube
Oct 29, 2020·The American Journal of Hospice & Palliative Care·Ambereen K MehtaMartina Wiedau-Pazos
Jan 23, 2021·Scientific Reports·Amirali ToossiVivian K Mushahwar
Dec 3, 2020·ERJ Open Research·Petra KotanenWaltteri Siirala
Aug 24, 2021·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Paul MehtaKevin Horton
Sep 30, 2021·NPJ Genomic Medicine·Allison A DilliottRobert A Hegele
Jan 12, 2022·Annals of Clinical and Translational Neurology·Jonathan S KatzJonathan D Glass
Jan 14, 2022·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Paul MehtaD Kevin Horton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.